CJMBCallan JMB Inc.
The schedule
- Thu15Oct
Assessment of President Trump’s trade policies and domestic infrastructure incentives on the Integrated Freight & Logistics sector.
- Mon15Feb
Preliminary full-year results and management's roadmap for a potential turnaround in fiscal year 2027.
- Wed12May
The Q3 report will provide the critical update for the end-of-year peak logistics season.
- Tue10Aug
Past
- Thu13Aug
Actual outcome: Bull
Callan JMB reported Q2 2026 earnings that met expectations, with EPS coming in exactly in-line at -$0.58. Shortly after the release, the company announced it had regained compliance with Nasdaq's minimum bid price requirement, removing a major delisting risk. This positive regulatory update, alongside stable earnings, drove a 15.2% rally that pushed the stock well past the bull target.
Second-quarter results will reveal if the integrated freight model is gaining traction under new logistics initiatives.
- Fri10Jul
Actual outcome: Bull · $1.21 at outcome
Callan JMB announced a strategic partnership with Alabama State University to advance U.S. pharmaceutical manufacturing, which management noted could represent a potential $414 million five-year revenue opportunity. This massive potential revenue pipeline significantly overshadowed prior liquidity concerns, driving a 57.9% rally in the stock as investors priced in the transformative growth prospects.
Management is expected to address the company's limited runway as cash reserves of $2.1M are offset by negative free cash flow.
- Fri15May
Actual outcome: Bear · $0.79 at outcome
Despite meeting EPS estimates of -$0.58 and announcing an expanded public sector infrastructure engagement, the stock plummeted 22.2% to well below the bear floor. The severe negative reaction indicates that the underlying financial results and outlook failed to alleviate concerns following a difficult 2025, prompting a significant sell-off.
CJMB reports first-quarter results following a difficult 2025 where revenue fell 14% YoY to $1.16M.
